Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to be beneficial in the prevention of colorectal and other types of cancer in humans and murine models. 1, 2 This chemopreventive effect is most frequently attributed to cyclooxygenase (COX) inhibition. Expression of the COX-2 isoform has been particularly well studied and is known to be rapidly induced by growth factors and tumor promoters.
Overexpression of COX-2 has been reported in premalignant and malignant lesions derived from a broad spectrum of tissues, including lung, breast, prostate, bladder and the gastrointestinal tract. 3 Deletion of COX-2 in cancer-prone mice suppresses tumor formation, 4 and selective COX-2 inhibitors have been shown to provide effective chemoprevention in humans and animal models of carcinogenesis. 5, 6 These observations suggest that overexpression of COX-2 is an early event in tumorigenesis and may play a role in the progression of precursor lesions to malignant neoplasms. As such, COX-2 may be a suitable candidate molecule for targeted cancer therapies.
Peroxisome proliferator-activated receptor gamma (PPARg) is a transcription factor belonging to the nuclear receptor superfamily. 7, 8 It appears to play a role in tumorigenesis, although the exact nature of that role has yet to be defined. A number of studies have shown that PPARg is expressed in several types of human cancers but not in the normal tissues from which these cancers are derived. 9 PPARg agonists have been shown to promote tumorigenesis in cancerprone mice; [10] [11] [12] however, the same agonists have also induced differentiation and slowed the growth of human tumor xenografts in other murine models. [13] [14] [15] [16] [17] Studies of PPARg and COX-2 expression in human skin have yielded mixed results. Immunohistochemical analyses of COX-2 expression in benign nevi and malignant melanomas generally showed an increase in COX-2 expression with cancer progression. [18] [19] [20] Similar studies of PPARg expression did not detect a correlation with tumor progression but did suggest that an association with COX-2 might exist. 21, 22 Interestingly, PPARg agonists did not reduce skin tumor formation in two well-characterized models of murine skin carcinogenesis 23 but did inhibit the growth of human melanoma cell lines in vitro. 24, 25 In an effort to clarify whether PPARg and COX-2 are suitable molecular markers of melanoma progression, we studied their expression in benign nevi and primary and metastatic melanomas using immunohistochemistry. The data show a progressive increase in COX-2 expression during the malignant progression of melanocytic tumors. Similarly, melanomas, but not benign melanocytic lesions, show increased PPARg expression. To our knowledge, the data contained herein represent the first immunohistochemistry study to correlate PPARg expression with progression of malignant melanoma.
Methods
Histopathological specimens were selected from the files of the Department of Pathology at Northwestern University, Chicago, IL, USA. Each case was independently reviewed by two pathologists (L. K. D and J. A. R), and a consensus was obtained for any discrepant cases.
Immunohistochemical analysis for COX-2 and PPARg was performed on 38 benign nevi (20 compound, 16 intradermal and 2 junctional), 32 primary melanomas (15 superficial spreading melanomas, 13 nodular melanomas, 2 lentigo maligna melanomas and 2 in situ melanomas) and 29 metastatic melanomas. In six cases, primary and metastatic melanomas were obtained from the same patient. Routine hematoxylin and eosin-stained sections were performed for histopathological evaluation.
Formalin-fixed, paraffin-embedded slides were stained using monoclonal antibodies against PPARg (dilution 1 : 100; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or COX-2 (catalog number 160112; dilution 1 : 100; Cayman Chemical, Ann Arbor, MI, USA) and a standard avidin-biotin-peroxidase complex (ABC) immunoperoxidase procedure. Nuclear staining for PPARg was classified into four grades on a scale of 0-3 based on the percentage of positive cells as follows: a score of 0 was given to specimens with 0% nuclear staining, a score of 11 was given to specimens with 1-9% nuclear staining, a score of 21 was given to specimens with 10-50% nuclear staining and a score of 31 was given to specimens with greater than 50% nuclear staining. COX-2 staining was scored as either weak or strong based on the intensity of cytoplasmic staining.
Fisher's exact test was used to determine statistical significance. The chi-square test was used to determine independence. A p-value of , 0.05 was considered statistically significant.
Results

COX-2 expression increases with malignant progression of melanocytic lesions
Virtually all the melanocytic lesions studied showed some level of COX-2 expression. A cytoplasmic pattern of staining was observed (Fig. 1) . As a significant number of cases showed a faint background blush, we interpreted COX-2 staining as either strong or weak instead of as a percentage of immunopositive cells. Specimens designated as strong showed intense and crisp cytoplasmic staining. Strong expression of COX-2 was seen in 33% (33/99) of all lesions studied. The percentage of specimens with strong expression of COX-2 was 3% (1/38) in benign nevi, 38% (12/32) in primary melanomas and 69% (20/29) in metastatic melanomas ( Fig. 2 and Table 1 ). Fisher's exact test showed that these differences were statistically significant when comparing benign nevi and primary melanomas (p ¼ 0.0003) as well as primary and metastatic melanomas (p , 0.0001, Table 2 ). These data show a progressive increase in COX-2 expression during the malignant progression of melanocytic tumors.
We then compared COX-2 expression in various melanoma subtypes. Thirty-eight percent (5/13) of nodular melanomas, 40% (6/15) of superficial spreading melanomas and 50% (1/2) of lentigo maligna melanomas exhibited strong COX-2 expression. There was no statistically significant association between increased levels of COX-2 and melanoma subtype using Fisher's exact test. Of note, we observed enhanced COX-2 expression in the periphery of two nodular melanomas (40%, 2/5), consistent with a previous study. 19 In our study, of the six individuals who had both primary and metastatic melanomas, only two showed strong COX-2 staining of their primary melanomas. These results suggest that strong COX-2 expression in a primary melanoma is not a prognosticator of future metastatic disease, although it is probable that our study was not adequately powered to detect a true difference in this subgroup.
PPARg is expressed at high levels in primary and metastatic melanomas Of the 99 samples studied, 22 (22%) showed immunoreactivity against PPARg (. 10% immunopositive keratinocytes). Specifically, 3% (1/38) benign nevi, 28% (9/32) primary melanomas and 41% (12/ 29) metastatic melanomas expressed PPARg (Table 1) . A nuclear staining pattern was predominantly seen (Fig. 3) , with cytoplasmic staining of PPARg noted in only one metastatic melanoma specimen. Fisher's exact test (Table 2) showed that these differences were statistically significant when comparing benign nevi and primary melanomas (p ¼ 0.004) and even more significant when comparing benign nevi and metastatic melanomas (p , 0.0001). While there appeared to be a trend toward increased PPARg immunoreactivity in metastatic melanomas compared with primary melanomas, this relationship did not achieve statistical significance (p ¼ 0.30). However, it is important to note that . 50% nuclear staining was only seen in metastatic melanomas (14%, 4/29, Table 3 ). Overall, the data show that increased PPARg expression occurs in melanomas but not in benign melanocytic lesions.
When we compared PPARg expression in various melanoma subtypes, 31% (4/13) of nodular melanomas, 27% (4/15) of superficial spreading melanomas and 50% (1/2) of lentigo maligna melanomas exhibited PPARg immunoreactivity. These results showed no statistically significant association between increased expression of PPARg and melanoma subtype using Fisher's exact test. In our study, of the six individuals who had both primary and metastatic melanomas, only two had primary melanomas that expressed PPARg. These results suggest that PPARg expression in a primary melanoma is not a prognosticator of future metastatic disease, although we cannot rule it out completely because of our limited sample size.
Discussion
Identifying molecular markers of cancer progression is critical for sustaining the current focus on targeted cancer therapies and rational drug design. An early intervention capable of interrupting or reversing disease progression would be particularly useful in malignant melanoma, where the current standards of care for metastatic disease have not resulted in a significant survival benefit. Targeted therapies could also be used as an adjunct to surgical excision in patients with localized disease who are at high risk of developing future metastases. To our knowledge, this is the first study to report increased expression of PPARg in human malignant melanoma. This finding may explain why melanoma cell lines appear susceptible to the antiproliferative effects of selective PPARg ligands, such as thiazolidinediones. 21, 25 In this study, we show that PPARg is expressed in a significant proportion of primary and metastatic melanomas but rarely expressed in benign nevi. Furthermore, . 50% nuclear staining was only seen in metastatic melanomas, suggesting that PPARg may have a role in the modulation of tumor invasion. We considered the possibility that strong expression of PPARg in a primary melanoma might predict future metastases. However, our study was not adequately powered to perform this analysis. It is nonetheless interesting to note that thiazolidinediones were recently shown to inhibit cell migration and invasion in human breast and pancreatic cell lines. 26, 27 Our data suggest that similar results may be seen in melanoma as well.
There are differing reports on the cellular localization of PPARg in the skin. Some studies have observed a granular cytoplasmic pattern, while others have noted nuclear staining. 21, 22 Our results are consistent with those obtained by others who used the same PPARg antibody, suggesting that reagent selection may influence apparent localization. It is also possible that the discrepancy between the data described in Nijsten et al. 22 and those described herein is because of tumor-specific differences in PPARg localization.
Increased expression of PPARg has been reported in a wide range of human cancers. In melanoma cell lines, PPARg agonists appear to suppress cellular proliferation and induce differentiation. 21, 24, 25, 28 However, inhibition of PPARg has produced similar results in other cancer types, including oral squamous cell carcinomas and hepatocellular carcinomas. 29, 30 We are not certain why this discrepancy occurs, but it may be the result of off-target effects of PPARg ligands or inherent differences between cell lines. Strong COX-2 expression was observed in both primary and metastatic melanomas but rarely in benign nevi. Of note, we found that metastatic melanomas were significantly more likely to have strong COX-2 expression than primary melanomas. Our results are consistent with previous studies, 19, 20 although we further extend the findings of Kuzbicki et al. to include distant cutaneous metastases as well as lymph node metastases. The data also raise the possibility that COX-2 promotes melanoma cell invasiveness. Our preliminary analysis did not detect a correlation between strong COX-2 expression in a primary melanoma and the presence of metastatic disease, but we recognize that the small sample size makes it difficult to rule out a type II error. Pharmacologic inhibition of COX-2 in melanoma cell lines has not consistently reduced prostaglandin E2 production or tumor cell invasiveness. 19, 31 It is interesting to speculate whether this is related to offtarget effects of NSAIDs, as a COX-independent mechanism of tumor suppression by these compounds has been shown. [32] [33] [34] Additional studies to clarify the role of COX-2 in melanoma progression and invasion seem to be warranted.
Studies on colorectal cancer have suggested that COX-2 and PPARg may have opposing effects on tumorigenesis. 35 More recently, an immunohistochemical study showed that COX-2-positive squamous cell carcinomas and actinic keratoses were more likely to express PPARg or its isoform, PPARb. 22 As such, we expected to see a correlation between COX-2 and PPARg expression in our study. A chi-square test for independence surprisingly did not show a relationship between COX-2 and PPARg. While we cannot say for certain why this discrepancy occurred, it is possible that cancer-specific differences may be involved.
Our study examines the expression patterns of PPARg and COX-2 in melanocytic lesions of the skin. The data suggest that both proteins play a role in the development and biological behavior of melanomas.
More importantly, increased expression of these markers in melanoma may enable us to tailor treatment to selectively target malignant cells. The prothrombotic and gastrointestinal complications of COX-2 inhibitors have raised concerns about their long-term safety, although these risks may be outweighed by a potential benefit in survival in high-risk, disseminated or unresectable disease. Our data showing increased PPARg expression in primary and metastatic melanomas also provide an explanation for the observed efficacy of thiazolidinediones in melanoma cell lines. As such, drugs that target COX-2 or PPARg, particularly those with favorable safety profiles, may be effective adjuncts in the treatment of melanoma. 
